TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Effectiveness of UroLift: LIFT Pivotal Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males age of 50 years or older diagnosed with symptomatic benign prostatic hyperplasia (BPH)~Exclusion Criteria:~* Size, volume,length of prostate

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UroLift System (Type: ACTIVE_COMPARATOR): The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
- Cystoscopy (Type: SHAM_COMPARATOR): The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
- Crossover (Type: ACTIVE_COMPARATOR): Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Celecoxib After Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography~Exclusion Criteria:~* Acute ST elevation MI~* Left main disease~* Contraindications to aspirin, clopidogrel or celecoxib~* Severe congestive heart failure~* Expected survival \< 2 years~* Hepatic dysfunction~* Currently taking NSAIDs or any COX-2 inhibitor~* Renal dysfunction~* Use of warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Celecoxib (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Inhalation vs. Intravenous Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Elective surgery Adult, age \>= 18 years old Scheduled for general anesthesia Medically fit and able to safely go any of the four anesthetic inductions in the study~Exclusion Criteria:~Emergency surgery, or any other aspiration risk Minor, age \<18 Pregnant Febrile illness Contraindication to nasal instrumentation Allergy to propofol Malignant hyperthermia Requiring Total Invravenous Anesthesia (TIVA) Inability to oxygenate on less than 50% FiO2 Intra-cranial surgery Receiving vasoactive medications Significant valvular heart disease Unstable cardiac disease Surgery requiring prone or lateral positioning Contraindication to nitrous oxide Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- sevoflurane in 100% oxygen, age <56 (Type: ACTIVE_COMPARATOR): The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
- sevoflurane in 50% nitrous, age <56 (Type: ACTIVE_COMPARATOR): The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
- propofol, age <56 (Type: ACTIVE_COMPARATOR): The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
- propofol with phenylephrine, age <56 (Type: ACTIVE_COMPARATOR): The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
- sevoflurane in 100% oxygen, age >55 (Type: ACTIVE_COMPARATOR): The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age \>55.
- sevoflurane in 50% nitrous, age >55 (Type: ACTIVE_COMPARATOR): The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age \>55.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aneurysmal SAH confirmed by angiography~2. Hemoglobin \< 12.5 gm/dl~3. One of the following:~   * Considered at increased risk for vasospasm by care team~  * Angiographic vasospasm~  * Delayed ischemic deficit~4. Able to be studied within 2 weeks after subarachnoid hemorrhage~Exclusion Criteria:~1. Active Coronary Artery Disease~2. Severe congestive heart failure~3. Jehovah's witness~4. Unable to obtain appropriately matched blood~5. Other contraindications for transfusion~6. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transfusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identifies as a man~* Age 18-35 at enrollment~* Reports having anal sex with a man or trans woman in the past 12 months and one or more of the following criteria in the past 12 months:~  * Any condomless anal sex (not in a mutually monogamous relationship with an HIV-negative partner)~ * Two or more anal sex partners~ * Self-reported STI (gonorrhea, chlamydia, syphilis)~ * Having a known HIV-positive sexual partner~* HIV-negative as determined by a negative 4th generation HIV test at screening and negative rapid 4th generation test at enrollment~* Currently taking PrEP or interested in initiating PrEP~* Eligible to take PrEP~  * Creatinine clearance ≥60 ml/min as estimated by Cockcroft-Gault equation at screening~ * Hepatitis B surface antigen (HBsAg) negative~* Willing and able to provide written informed consent~* Able to read and speak English~* Smartphone ownership compatible with DOT Diary~* Meets local locator requirements~Exclusion Criteria:~* Any reactive HIV test at screening or enrollment~* Signs or symptoms of acute HIV infection at screening or enrollment~* History of pathological bone fracture not related to trauma~* Taking nephrotoxic medications~* History of participation in the active arm of an HIV vaccine trial~* In a mutually monogamous sexual relationship with an HIV-negative partner for the past 12 months~* Does not live, work or play in Atlanta Metropolitan Area, San Francisco, Alameda, Marin, Contra Costa, Santa Clara, or San Mateo Counties~* Unable to commit to study participation for 8 weeks~* Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- DOT Diary Optimization Intervention (Type: EXPERIMENTAL): DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 60 years of age~* Undergoing CABG with/without valve (aortic and/or mitral) procedure requiring bypass~Exclusion Criteria:~* Pre-operative Left Ventricular Ejection Fraction (LVEF) \< 30%~* Emergent or urgent procedures, aortic surgery~* Pre-existing cognitive impairment (defined based on a short screening assessment), Parkinson's disease, Alzheimer's disease, recent seizures (\<3 months)~* Prophylactic medications for cognitive decline~* Serum creatinine \> 2 mg/dl~* Liver dysfunction (liver enzymes \> 4x the baseline, since patients will have a baseline liver function tests), history and exam suggestive of jaundice~* Known history of alcohol or drug abuse (\>10 drinks per week)~* Hypersensitivity to any of the study drug and percutaneous procedures~* Non-English speaking

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV acetaminophen & IV propofol (Type: EXPERIMENTAL): 20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
- IV acetaminophen & IV dexmedetomidine (Type: EXPERIMENTAL): A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
- IV propofol & placebo (Type: ACTIVE_COMPARATOR): 20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
- IV dexmedetomidine & placebo (Type: ACTIVE_COMPARATOR): 0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Non-Hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. No restrictions regarding gender.~* Patients with histologically or cytologically confirmed indolent B cell Non-Hodgkin's lymphoma or mantle cell lymphoma.~* Patients who had not received treatment for at least 4 weeks (for at least 12 weeks in the case of antibody therapy) after completion of prior therapy and who are judged to carry no effect from the prior therapy.~* Patients aged from 20 to less than 75 years.~* Performance Status (P.S.): 0 or 1.~* Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung, liver, and kidney functions).~* Patients from whom written consent to participate in this study has been obtained.~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded.~* Patients with apparent infections.~* Patients with serious complications (hepatic failure or renal failure).~* Patients with complication or history of serious heart failure (e.g. cardiac infarction, ischemic heart disease).~* Patients with serious digestive symptoms (nausea/ vomiting/ diarrhea).~* Patients who are known to be positive for HBV, HCV or HIC.~* Patients receiving other investigational drugs within 3 months before registration in the study.~* Patients with allogenic bone-marrow transplant.~* Women who are pregnant, of childbearing potential, or lactating.~* Patients who do not agree to contraception.~* Otherwise, patients who are judged by the investigator as being unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must provide written informed consent.~* Must be a candidate for either treatment with Radiofrequency Ablation (RFA) or endovenous laser.~Exclusion Criteria:~* Subjects who require additional treatments in either leg within 30 days before or after the study procedure.~* Subjects who are participating in another investigational study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Seg. RF Ablation & ClosureFAST catheter (Type: ACTIVE_COMPARATOR): Seg. RF Ablation \& ClosureFAST catheter
- Endovenous Laser (Type: ACTIVE_COMPARATOR): Treatment invention of venous disease with an Endovenous Laser.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a history of chronic, moderate to severe plaque psoriasis (PASI ≥12; BSA (body surface area) ≥10 and IGA mod 2011 (Investigator's Global Assessment) ≥3) for at least 6 months~* patient candidates for systemic therapy.~* informed consent.~Exclusion Criteria:~* previous treatment with agent targeting IL-17 (interleukine-17) or IL-17 receptor.~* recent treatment with topical treatment (2 weeks), systemic agents (4 weeks for methotrexate, Ciclosporine A; systemic retinoids and other systemic treatment), TNF (tumor necrosis factor) inhibitors (3 months) or IL-12/23 inhibitors (6 months).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Prior to Surgery:~* Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive~* Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic block) not to include base wedge procedure~After Surgery:~* Subject reported pain of ≥4 on the NPRS, and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within 9 hours after removal of the popliteal sciatic block on Day 1~* Subject is lucid and able to follow commands~* All analgesic guidelines were followed during and after the bunionectomy~Exclusion Criteria:~Prior to Surgery:~* History in the past 10 years of malignancy, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ~* History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)~* History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN)~* History of peripheral neuropathy~* A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses~* Prior medical history of bunionectomy or other foot surgery~* Intolerant of or unwilling to receive hydrocodone, acetaminophen, or ibuprofen~* For female subjects: Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose~* For male subjects: Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose~After Surgery:~* Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair; or experienced medical complications during the bunionectomy that, in the opinion of the investigator, should preclude randomization~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VX-150 (Type: EXPERIMENTAL): None
- Hydrocodone Bitartrate/Acetaminophen (HB/APAP) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have De novo glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendrogliomas, mixed anaplastic oligoastrocytomas, gliosarcoma of the Brain, not involving the brain stem or optics chiasm, diagnosed following biopsy or tumor removal.~* Age \> 18 years~* Given written consent~* Adequate bone marrow reserve(hemoglobin \> 10 grams, Absolute neutrophil count \> 1500 / mm3, platelets \> 100,000/ mm3)~* Normal renal function(BUN \< 24 mg/dL, Creatinine \< 1.3 mg/dL)~* Normal liver function(Total Bilirubin \< 1.5 mg/dL, SGPT/ALT \< 60 U/L)~Exclusion Criteria:~* Have a Karnofsky score of \< 60 \[Appendix B\] or age \< 18 years.~* Prior chemotherapy and/or radiotherapy of their glioblastomamultiforme, anaplastic astrocytoma, anaplastic oligodendrogliomas, mixed anaplastic oligoastrocytomas, gliosarcoma.~* Tumors located in the brainstem or optic chiasm.~* Prior radiation therapy to the brain~* Prior chemotherapy within the past 6 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hypofractionation Radiotherapy+Temozolomide (Type: EXPERIMENTAL): Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Non-pregnant Hemodynamically stable Reproductive-aged women \>18 years Present with acute uterine bleeding~Exclusion Criteria:~Pregnant Non-hemodynamically stable \<18 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete